<h2 dir="ltr">HER2+ Gastric Cancer</h2>
HER2-positive gastric cancer is a subtype of stomach cancer characterized by the overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) protein. This biomarker is present in approximately 15&ndash;20% of gastric and gastroesophageal junction (GEJ) adenocarcinomas and is associated with more aggressive disease and poorer prognosis. The identification of HER2 status has become essential in guiding treatment, as targeted therapies like trastuzumab have shown improved outcomes when combined with chemotherapy in HER2+ patients.&nbsp;
<h2 dir="ltr">Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Total incident cases of gastric cancer (including GEJ)
</li>
<li dir="ltr" aria-level="1">
Gender-specific cases of gastric cancer (including GEJ)
</li>
<li dir="ltr" aria-level="1">
Stage-specific cases of gastric cancer (including GEJ)
</li>
<li dir="ltr" aria-level="1">
Total incident cases of HER2+ gastric cancer (including GEJ)
</li>
<li dir="ltr" aria-level="1">
Total incident cases of advanced HER2+ gastric cancer (including GEJ)
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-epidemiology-forecast-insight">HER2+ Gastric Cancer Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the 7MM reported approximately 211.5K incident cases of gastric cancer (including GEJ), with numbers projected to rise by 2034.
</li>
<li dir="ltr" aria-level="1">
Japan accounted for about 60% of HER2+ gastric cancer cases, while the EU4 and the UK together made up roughly 25%.
</li>
<li dir="ltr" aria-level="1">
Among EU4 and the UK, Germany had the highest number of HER2+ gastric cancer cases (~3.4K), followed by Italy (~3K), with the UK reporting the fewest.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-market">HER2+ Gastric Cancer Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
The HER2+ gastric cancer market (including GEJ) in the 7MM is valued at around USD 700 million in 2024, with growth expected through 2034.
</li>
<li dir="ltr" aria-level="1">
In 2024, Germany leads the EU4 market, while the UK has the smallest share.
</li>
<li dir="ltr" aria-level="1">
Trastuzumab &plusmn; Chemotherapy generated the highest revenue in 2024 (~USD 140 million) in the U.S.
</li>
<li dir="ltr" aria-level="1">
By 2034, ENHERTU is projected to be the top-earning emerging therapy in the EU4 and the UK.
</li>
</ul>
<h3 dir="ltr">HER2+ Gastric Cancer Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
The increasing use of HER2-targeted therapies, such as trastuzumab and emerging antibody-drug conjugates (e.g., trastuzumab deruxtecan), is significantly driving market growth by improving survival rates and offering more personalized treatment approaches for HER2+ gastric cancer patients.
</li>
<li dir="ltr" aria-level="1">
Rising awareness and implementation of HER2 testing protocols in gastric and gastroesophageal cancers have enhanced patient stratification, enabling earlier and more accurate selection for HER2-targeted treatments, thus expanding the eligible patient pool.
</li>
</ul>
<h3 dir="ltr">HER2+ Gastric Cancer Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
Despite initial response to HER2-targeted therapies, treatment resistance and disease progression remain significant challenges. The lack of well-established second- or third-line HER2-directed therapies limits long-term disease management.
</li>
<li dir="ltr" aria-level="1">
HER2 expression in gastric cancer is often heterogeneous and less uniform compared to breast cancer, making diagnosis and treatment efficacy more complex and variable, thereby hindering consistent therapeutic outcomes across all patients.
</li>
</ul>
<h3 dir="ltr">HER2+ Gastric Cancer Key Therapies</h3>
<ul>
<li dir="ltr" aria-level="1">
ZIIHERA (zanidatamab)
</li>
<li dir="ltr" aria-level="1">
Rilvegostomig
</li>
<li dir="ltr" aria-level="1">
HLX22 (AC101)
</li>
<li dir="ltr" aria-level="1">
Evorpacept (ALX148)
</li>
<li dir="ltr" aria-level="1">
TUKYSA (tucatinib)
</li>
</ul>
And others.&nbsp;
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-pipeline-insight">HER2+ Gastric Cancer Key Players</a></h3>
<ul>
<li dir="ltr" aria-level="1">
Merck
</li>
<li dir="ltr" aria-level="1">
Daiichi Sankyo
</li>
<li dir="ltr" aria-level="1">
AstraZeneca
</li>
<li dir="ltr" aria-level="1">
Jazz Pharmaceuticals, BeiGene, and Zymeworks
</li>
<li dir="ltr" aria-level="1">
Shanghai Henlius Biotech and AbClon
</li>
<li dir="ltr" aria-level="1">
ALX Oncology
</li>
<li dir="ltr" aria-level="1">
Pfizer
</li>
<li dir="ltr" aria-level="1">
Bayer
</li>
<li dir="ltr" aria-level="1">
Enliven Therapeutics
</li>
<li dir="ltr" aria-level="1">
SystImmune
</li>
</ul>
And others.

HER2+ Gastric Cancer Market

HER2+ Gastric Cancer Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape